1630 – 1730
Michael Boivin, Clinical Pharmacist Consultant, Certified Diabetes Educator (CDE) and Certified Tobacco Educator (CTE)
Tobacco is the leading cause of preventable death. It affects nearly every organ in the body. Tobacco use in Canada has decreased significantly from historic highs in the 1960’s but have stabilized over the last few years with 15.8% of Canadians 12 years of age and older being a daily or occasional smoker.
Cardiovascular disease and macrovascular complications are the leading cause of death in people with type 2 diabetes. Diabetes guidelines stress the importance of complication risk reduction in patients with diabetes and to not solely focus on glycemic control.
This presentation will focus on cardiovascular risk reduction in patients with type 2 diabetes. It will stress on the importance on smoking cessation to prevent and reduce complication risk in people with diabetes. Practical tips will be shared in how to manage people with type 2 diabetes who use tobacco. It will also review the current recommendations to reduce cardiovascular risk in this large patient population.
- Review the impact of tobacco use in people with prediabetes and diabetes
- Ensure people with type 2 know their ABCDESSS to reduce their cardiovascular risk
- Determine effective methods of approaching the topic of smoking cessation in individuals who use tobacco
- Review the different pharmacotherapy options to improve smoking cessation rates in people with diabetes
- Discuss the strategies to reduce cardiovascular risk in people with type 2 diabetes
Posted in: Friday, October 16, 2020